Serial No.: 09/398,610

Filed: September 17, 1999

Page

: 3eptemo

2. (Amended) The method of claim 1, wherein the first member of the fusion protein is an immunoglobulin subunit.

Attorney's Docket No.: 10275-137001

- 3. (Amended) The method of claim 1, wherein the first member is fused to the second member and the first member includes a subunit of a targeting molecule and the second member encodes a cell toxin.
- 4. (Amended) The method of claim 1, wherein the first member includes a subunit of an immunoglobulin specific for a tumor antigen.
- 5. (Amended) The method of claim 4, wherein the tumor antigen is from the group consisting of carcinoembryonic antigen (CEA), a transferrin receptor, TAG-72, and an epidermal growth factor.
- 6. (Amended) The method of claim 1, wherein the second member is an RNase.
  - 7. (Reiterated) The method of claim 6, wherein the RNase is RNase A.
- 8. (Amended) The method of claim 1, wherein the second member is angiogenin.
- 10. (Amended) The method of claim 2, wherein the immunoglobulin subunit of the fusion protein is a human antibody or antigen binding portion thereof.
- 11. (Amended) The method of claim 1, wherein the fusion protein is produced in the milk of the mammal at concentrations of at least about 0.5 mg/ml.
- 12. (Amended) The method of claim 1, wherein the fusion protein is produced in the milk of a transgenic mammal at concentrations of at least about 1.0 mg/ml.

. (

a 2

73

Serial No.: 09/398,610

Filed: September 17, 1999

Page: 3

13. (Amended) The method of claim 2, wherein the immunoglobulin subunit of the fusion protein is a humanized antibody or antigen binding portion thereof.

Docket No.: 10275-137001

a

- 14. (Amended) The method of claim 1, wherein the transgene encoding the fusion protein is a nucleic acid which comprises:
  - (a) a mammary epithelial specific promoter;
- (b) a nucleotide sequence which encodes a signal sequence which can direct the secretion of the fusion protein;
  - (c) one or more nucleotide sequences which encode the fusion protein.
  - 15. (Cancel) An isolated nucleic acid construct, comprising
  - (a) optionally, an insulator sequence;
  - (b) a mammary epithelial specific promoter;
- (c) a nucleotide sequence which encodes a signal sequence which can direct the secretion of the fusion protein e.g., a signal from a milk protein;
- (d) optionally, a nucleotide sequence which encodes a sufficient portion of the amino terminal coding region of a secreted protein, e.g., a protein secreted into milk, to allow secretion, e.g., in the milk of a transgenic mammal, of the fusion protein;
  - (e) one or more nucleotide sequences which encode the fusion protein; and
- (f) optionally, a 3' untranslated region from a mammalian gene, e.g., a mammary epithelial specific gene (e.g., a milk protein gene).

In another aspect, the invention features a pharmaceutical or nutraceutical composition having an effective amount of fusion protein, e.g., an immunoglobulin-enzyme fusion protein as described herein, a pharmaceutically acceptable carrier.

In a preferred embodiment, the composition includes milk.

Q.4

16. (Amended) A non-human transgenic mammal which includes a transgene that encodes a fusion protein, the transgene comprising: a mammary epithelial specific promoter, a nucleotide sequence which encodes a signal sequence which can direct the

Serial No.: 09/398,610

Filed: September 17, 1999

Page

: 4

secretion of the fusion protein, and one or more nucleotide sequences encoding the fusion protein, wherein the fusion protein includes a first member and a second member, the second member is an enzyme produced in the milk of a transgenic mammal in active form, and the fusion protein is produced in the milk of the transgenic mammal at a concentration of at least about 0.1 mg/ml.

ocket No.: 10275-137001

17. (Amended) The transgenic mammal of claim 16, which can produce the fusion protein into its milk at concentrations of at least about 0.5 mg/ml.--

Please add claims 18-35.

- -- 18. (New) The method of claim 2, wherein the immunoglobulin subunit of the fusion protein is a chimeric antibody or antigen binding portion thereof.
- 19. (New) The method of claim 4, wherein the tumor antigen is a transferrin receptor.
- 20. (New) The method of claim 1, wherein the first member of the fusion protein is directly fused to the second member.
- 21. (New) The method of claim 1, wherein the first member of the fusion protein is linked to the second member by a linker sequence.
  - 22. (New) The method of claim 1, wherein the transgenic mammal is a goat.
  - 23. (New) The method of claim 1, wherein the transgenic mammal is a cow.
- 24. (New) The transgenic mammal of claim 16, wherein the first member of the fusion protein is an immunoglobulin subunit.

N &

Serial No.: 09/398,610

: September 17, 1999

Page

: 5

25. (New) The transgenic mammal of claim 16, wherein the first member is fused to the second member and the first member includes the subunit of a targeting molecule and the second member encodes a cell toxin.

ocket No.: 10275-137001

- 26. (New) The transgenic mammal of claim 16, wherein the first member of the fusion protein includes a subunit of an immunoglobulin specific for a tumor antigen.
- (New) The transgenic mammal of claim 26, wherein the tumor antigen is 27. from the group consisting of carcinoembryonic antigen (CEA), a transferrin receptor, TAG-72, and an epidermal growth factor.
- 28. (New) The transgenic mammal of claim 16, wherein the second member of the fusion protein is an RNase.
- 29. (New) The transgenic mammal of claim 28, wherein the RNase is RNase A.
- (New) The transgenic mammal of claim 16, wherein the second member 30. of the fusion protein is angiogenin.
- (New) The transgenic mammal of claim 24, wherein the immunoglobulin 31. subunit of the fusion protein is a human antibody or antigen binding portion thereof.
- 32. (New) The transgenic mammal of claim 24, wherein the immunoglobulin subunit of the fusion protein is a humanized antibody or antigen binding portion thereof.
- (New) The transgenic mammal of claim 24, wherein the immunoglobulin 33. subunit of the fusion protein is a chimeric antibody or antigen binding portion thereof.

Serial No.: 09/398,610

Filed: September 17, 1999

Page: 6

34. (New) The transgenic mammal of claim 16, wherein the mammal is a

ocket No.: 10275-137001

goat.

35. (New) The transgenic mammal of claim 16, wherein the mammal is a

cow.--